In a recent phase 3 trial, the combination of nivolumab and ipilimumab was found to be more effective than traditional treatments in treating unresectable hepatocellular carcinoma. The study, sponsored by Bristol Myers Squibb, compared the combination to lenvatinib or sorafenib as first-line treatment for this type of liver cancer. The results showed significantly improved overall survival rates for patients receiving nivolumab and ipilimumab, providing hope for those with this difficult-to-treat cancer. This new treatment option could potentially change the standard of care for unresectable hepatocellular carcinoma.
Original Source: https://pubmed.ncbi.nlm.nih.gov/40349714/
